Tissue-engineered vascular grafts: a clinical-trial report examining comparative performance, gender-focused implications and potential effects on dialysis care pathways.
Key Takeaways
- Acellular tissue-engineered vessel outperformed autologous arteriovenous fistula for women on dialysis
- Trial stopped enrollment early after meeting its predefined primary superiority endpoint
- Supplemental biologics license application is planned in 2026 for adults at higher fistula failure risk